Skip to content

Attenuation of Tonal Tinnitus by Lateral Inhibition Therapy

Attenuation of Tonal Tinnitus by Lateral Inhibition Therapy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04807686
Acronym
TIL
Enrollment
29
Registered
2021-03-19
Start date
2019-07-19
Completion date
2021-12-31
Last updated
2021-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tinnitus

Brief summary

Lateral Inhibition Therapy (TIL) corrects the patient's hearing by notched amplification on the patient's listening soundtrack. This half-octave notch is targeted at tinnitus frequencies measured tonal. The device slightly increases the amplification around the notch, so that the cerebral cortex compensates for this gap in the sound spectrum, masking the crippling tinnitus at the same time. This research is based on a new algorithm developed by the SIEMENS Company which proposes an attenuation of tonal tinnitus by a TIL by notched amplification emitted by the hearing device, object of the study.

Detailed description

In France, up to 16 million people suffer from tinnitus or ringing in the ears daily. This parasitic sound that does not come from the patient's environment can interfere with each individual in a variable way, sometimes creating an insurmountable handicap which has not known any effective treatment validated to date. Lateral Inhibition Therapy (TIL) corrects the patient's hearing by notched amplification on the patient's listening soundtrack. This half-octave notch is targeted at tinnitus frequencies measured tonal. The device slightly increases the amplification around the notch, so that the cerebral cortex compensates for this gap in the sound spectrum, masking the crippling tinnitus at the same time. This research is based on a new algorithm developed by the SIEMENS Company which proposes an attenuation of tonal tinnitus by a TIL by notched amplification emitted by the hearing device, object of the study.

Interventions

DEVICEAuditory simulation

Each patient will be delivered each of the 2 auditory stimulation protocols considered in the context of the research: stimulation with a traditional algorithm called AT and stimulation with a notched-type algorithm called AE. The order in which will be carried out, for the same patient, each of these 2 protocols (AT then AE or AE then AT) will be randomized.

Sponsors

Dr Quemar
CollaboratorUNKNOWN
Ramsay Générale de Santé
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient over 18 years old. * Patient with disabling tonal tinnitus (THI score\> 40) for more than 6 months. * Patient with a hearing loss of at least 25dB, centered on the frequency of tinnitus and requiring hearing aids * Patient who has never used a hearing aid or a tinnitus masking system. * Patient who stopped all tinnitus treatment at least 1 month before the start of the study (drug treatment, psychotherapy). * Patient being willing to attend all of the visits planned as part of the study. * Patient affiliated or beneficiary of a social security scheme. * Patient having signed the free and informed consent

Exclusion criteria

* Minor patient. * Patient with hyperacusis * Patient already with a hearing aid or tinnitus masker. * Patient undergoing psychotropic or neurotropic drug treatments. * Patient with a history of psychological or psychiatric disorders. * Patient with a contraindication to wearing hearing aids. * Patient suffering from non-disabling tinnitus (THI score \<40). * Patient suffering from intermittent, non-tonal or pulsatile tinnitus. * Patient participating in another clinical study. * Protected patients: adults under guardianship, curatorship or other legal protection, deprived of their liberty by judicial or administrative decision. * Pregnant or breastfeeding woman

Design outcomes

Primary

MeasureTime frameDescription
Tinnitus Handicap Inventory2 monthsThe primary endpoint is the score (out of 100 points) obtained on the Tinnitus Handicap Inventory (THI), expressed in terms of variation from the baseline.

Countries

France

Contacts

Primary ContactJF OUDET
jf.oudet@ecten.eu+33683346567
Backup ContactMH Barba
mh.barba@ecten.eu+ 336 64 88 87 04

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026